Halozyme Therapeutics, Inc. $HALO Shares Newly Bought by Riverbridge Partners LLC

Riverbridge Partners LLC purchased a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the third quarter, Holdings Channel reports. The fund purchased 132,015 shares of the biopharmaceutical company’s stock, valued at approximately $14,574,000.

A number of other hedge funds have also made changes to their positions in the stock. Illinois Municipal Retirement Fund lifted its position in Halozyme Therapeutics by 14.0% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 103,565 shares of the biopharmaceutical company’s stock worth $11,434,000 after buying an additional 12,752 shares in the last quarter. Renasant Bank acquired a new stake in shares of Halozyme Therapeutics during the 3rd quarter valued at $242,000. Lido Advisors LLC purchased a new position in shares of Halozyme Therapeutics during the 3rd quarter valued at $465,000. Context Capital Management LLC purchased a new position in shares of Halozyme Therapeutics during the 3rd quarter valued at $15,435,000. Finally, Keybank National Association OH grew its holdings in shares of Halozyme Therapeutics by 31.2% during the 3rd quarter. Keybank National Association OH now owns 8,834 shares of the biopharmaceutical company’s stock valued at $975,000 after acquiring an additional 2,103 shares in the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $107.43, for a total transaction of $2,148,600.00. Following the transaction, the chief executive officer owned 767,780 shares in the company, valued at approximately $82,482,605.40. This trade represents a 2.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew Posard sold 18,996 shares of Halozyme Therapeutics stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $107.74, for a total transaction of $2,046,629.04. Following the completion of the sale, the director directly owned 58,839 shares of the company’s stock, valued at approximately $6,339,313.86. The trade was a 24.41% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 124,226 shares of company stock worth $13,370,893. 2.50% of the stock is currently owned by company insiders.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $102.98 on Wednesday. The firm has a market cap of $11.74 billion, a PE ratio of 26.20, a PEG ratio of 0.39 and a beta of 0.92. The firm’s 50 day moving average price is $115.07 and its 200 day moving average price is $85.05. The company has a debt-to-equity ratio of 13.50, a quick ratio of 3.60 and a current ratio of 3.88. Halozyme Therapeutics, Inc. has a twelve month low of $61.22 and a twelve month high of $134.00.

Halozyme Therapeutics (NASDAQ:HALO) last posted its earnings results on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.09. The firm had revenue of $492.97 million during the quarter, compared to analysts’ expectations of $491.63 million. Halozyme Therapeutics had a net margin of 26.93% and a return on equity of 751.81%. The company’s revenue was up 39.1% compared to the same quarter last year. During the same period in the previous year, the company earned $1.72 earnings per share. As a group, research analysts expect that Halozyme Therapeutics, Inc. will post 8.34 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on HALO. TD Cowen upped their price target on shares of Halozyme Therapeutics from $105.00 to $130.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. Morgan Stanley set a $109.00 price objective on Halozyme Therapeutics and gave the company a “reduce” rating in a research report on Wednesday. Citizens Jmp boosted their target price on Halozyme Therapeutics from $93.00 to $149.00 and gave the company a “market outperform” rating in a research note on Friday, November 6th. Leerink Partners downgraded Halozyme Therapeutics from an “outperform” rating to a “hold” rating and boosted their target price for the company from $110.00 to $117.00 in a research note on Friday, November 6th. Finally, JPMorgan Chase & Co. upped their target price on Halozyme Therapeutics from $78.00 to $79.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 3rd. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $108.18.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion. Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.